Arcturus Therapeutics (ARCT) Expected to Announce Earnings on Monday

Key Points

• Arcturus Therapeutics (NASDAQ: ARCT) is set to announce its Q2 2025 earnings results on August 11th, with analysts predicting an earnings loss of ($1.11) per share and revenue of $17.64 million.
• In the previous quarter, the company reported an EPS of ($0.52) and revenue of $29.38 million, exceeding analysts' expectations.
• Institutional investors now own approximately 94.54% of Arcturus Therapeutics' stock, with several hedge funds making significant investments in the company recently.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $17.64 million for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcturus Therapeutics Trading Down 2.6%

Shares of Arcturus Therapeutics stock traded down $0.32 on Thursday, reaching $11.90. 161,992 shares of the company's stock were exchanged, compared to its average volume of 432,564. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $25.88. The company has a market capitalization of $322.59 million, a P/E ratio of -4.70 and a beta of 2.26. The firm's 50-day moving average is $13.17 and its two-hundred day moving average is $13.40. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Scotiabank restated an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. HC Wainwright reiterated a "buy" rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Citigroup reaffirmed a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Wall Street Zen lowered Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 5th. Finally, Canaccord Genuity Group reduced their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.00.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently bought and sold shares of ARCT. AQR Capital Management LLC acquired a new stake in shares of Arcturus Therapeutics in the first quarter worth approximately $128,000. Millennium Management LLC purchased a new stake in Arcturus Therapeutics during the first quarter valued at about $4,892,000. Goldman Sachs Group Inc. grew its position in Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company's stock valued at $5,398,000 after purchasing an additional 42,636 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Arcturus Therapeutics in the first quarter worth approximately $701,000. Finally, Strs Ohio bought a new position in shares of Arcturus Therapeutics during the 1st quarter worth about $89,000. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.